Serum concentrations of extracellular fatty acid synthase in patients with steatohepatitis
J Marsillach, C Oliveras-Ferraros, R Beltran… - Clinical chemistry and …, 2009 - degruyter.com
Clinical chemistry and laboratory medicine, 2009•degruyter.com
Background: Fatty acid synthase (FASN) is an enzyme synthesized by the liver and plays an
important role in lipogenesis. The present study aimed to assess whether serum FASN
concentrations are altered in patients with chronic liver disease, and to investigate whether
its measurement may be a useful tool in the clinical evaluation of this derangement.
Methods: We investigated 93 patients with chronic liver disease (14 minimal change
disease, 79 steatohepatitis) and 100 control subjects. Serum FASN concentrations were …
important role in lipogenesis. The present study aimed to assess whether serum FASN
concentrations are altered in patients with chronic liver disease, and to investigate whether
its measurement may be a useful tool in the clinical evaluation of this derangement.
Methods: We investigated 93 patients with chronic liver disease (14 minimal change
disease, 79 steatohepatitis) and 100 control subjects. Serum FASN concentrations were …
Abstract
Background: Fatty acid synthase (FASN) is an enzyme synthesized by the liver and plays an important role in lipogenesis. The present study aimed to assess whether serum FASN concentrations are altered in patients with chronic liver disease, and to investigate whether its measurement may be a useful tool in the clinical evaluation of this derangement.
Methods: We investigated 93 patients with chronic liver disease (14 minimal change disease, 79 steatohepatitis) and 100 control subjects. Serum FASN concentrations were measured using ELISA.
Results: Patients had a significant increase in serum FASN concentration (p<0.001), which was specifically associated with the hepatic Knodell sub-index III of portal inflammation (p=0.019). In addition, serum FASN concentrations were significantly correlated with the circulating levels of the monocyte chemoattractant protein-1 (MCP-1) (Spearman ρ=0.375; p<0.001) and type III procollagen-N-peptide (P-III-P) (Spearman ρ=0.297; p<0.001).
Conclusions: Serum FASN concentrations are increased in patients with chronic liver impairment, and are associated with specific histological alterations and biochemical markers of portal inflammation. These data suggest that FASN measurement may contribute significantly to the evaluation of these patients.
Clin Chem Lab Med 2009;47:1097–9.
De Gruyter